
---
title: '为阿尔茨海默病设计的药物或可治疗胶质母细胞瘤'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202111/24/103931xmqa4azaut4wr20y.jpg'
author: 科学网
comments: false
date: Wed, 24 Nov 2021 10:32:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202111/24/103931xmqa4azaut4wr20y.jpg'
---

<div>   
<p style="line-height: 2em;"><span style="font-size: 24px; font-family: 黑体, SimHei;">东方不亮西方亮：</span></p><p style="line-height: 2em;"><span style="font-size: 24px; font-family: 黑体, SimHei;">为阿尔茨海默病设计的药物可能有希望治疗胶质母细胞瘤</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202111/24/103931xmqa4azaut4wr20y.jpg" title alt="122.jpg" referrerpolicy="no-referrer"><br></span></p><p style="line-height: 2em;"><a href="https://medicalxpress.com/news/2021-11-drug-alzheimer-disease-glioblastoma.html" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Glioblastoma (histology slide). Credit: Wikipedia/CC BY-SA 3.0</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据美国克利夫兰诊所（</span><a href="http://www.clevelandclinic.org/" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">Cleveland Clinic</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）</span>2021<span style="font-size: 18px; font-family: 宋体;">年</span>11<span style="font-size: 18px; font-family: 宋体;">月</span>23<span style="font-size: 18px; font-family: 宋体;">日提供的消息，克利夫兰诊所的新研究发现，最初用于治疗阿尔茨海默病的药物可能有望治疗胶质母细胞瘤（</span></span><a href="https://medicalxpress.com/news/2021-11-drug-alzheimer-disease-glioblastoma.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Drug designed for Alzheimer's disease may hold promise for treating glioblastoma</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">），胶质母细胞瘤是最常见、最致命的原发性脑肿瘤类型。相关研究结果于</span>2021<span style="font-size: 18px; font-family: 宋体;">年</span>11<span style="font-size: 18px; font-family: 宋体;">月</span>8<span style="font-size: 18px; font-family: 宋体;">日已经在《自然癌症》（</span></span><a href="https://www.nature.com/natcancer" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Nature Cancer</span></a><span style="font-size: 18px; font-family: "times new roman";">）杂志网站发表——</span><a href="https://www.nature.com/articles/s43018-021-00267-9#auth-Kui-Zhai" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Kui Zhai</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s43018-021-00267-9#auth-Zhi-Huang" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Zhi Huang</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s43018-021-00267-9#auth-Qian-Huang" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Qian Huang</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s43018-021-00267-9#auth-Weiwei-Tao" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Weiwei Tao</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s43018-021-00267-9#auth-Xiaoguang-Fang" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Xiaoguang Fang</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s43018-021-00267-9#auth-Aili-Zhang" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Aili Zhang</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s43018-021-00267-9#auth-Xiaoxia-Li" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Xiaoxia Li</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s43018-021-00267-9#auth-George_R_-Stark" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">George R. Stark</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s43018-021-00267-9#auth-Thomas_A_-Hamilton" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Thomas A. Hamilton</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s43018-021-00267-9#auth-Shideng-Bao" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Shideng Bao</span></a><span style="font-size: 18px; font-family: "times new roman";">. Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells. </span><a href="https://www.nature.com/natcancer" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Nature Cancer</span></a><span style="font-size: 18px; font-family: "times new roman";">, 2021, Volume 2, Pages1136–1151. </span><a href="https://www.nature.com/articles/s43018-021-00267-9#article-info" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Published: 08 November 2021</span></a><span style="font-size: 18px; font-family: "times new roman";">. </span><a href="http://dx.doi.org/10.1038/s43018-021-00267-9" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">DOI: 10.1038/s43018-021-00267-9</span></a><span style="font-size: 18px; font-family: "times new roman";">. </span><a href="http://dx.doi.org/10.1038/s43018-021-00267-9" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">http://dx.doi.org/10.1038/s43018-021-00267-9</span></a><span style="font-size: 18px; font-family: "times new roman";">.<span style="font-size: 18px; font-family: 宋体;">参与此项研究的除了来自克利夫兰诊所的研究人员之外，还有来自凯斯西储大学医学院凯斯综合癌症中心（</span>Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine<span style="font-size: 18px; font-family: 宋体;">）的研究人员。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">一类被称为</span>BACE1<span style="font-size: 18px; font-family: 宋体;">抑制剂（</span>BACE1 inhibitors<span style="font-size: 18px; font-family: 宋体;">）的药物曾经是治疗阿尔茨海默病（</span>Alzheimer's disease<span style="font-size: 18px; font-family: 宋体;">）最受期待的候选药物之一。它们通过抑制一种叫做</span>BACE1<span style="font-size: 18px; font-family: 宋体;">的蛋白质发挥作用，这种蛋白质负责在大脑中产生β</span>-<span style="font-size: 18px; font-family: 宋体;">淀粉样斑块（</span>β-amyloid plaques<span style="font-size: 18px; font-family: 宋体;">），而β</span>-<span style="font-size: 18px; font-family: 宋体;">淀粉样斑块是阿尔茨海默病的主要特征之一。然而，在临床试验（</span></span><a href="https://medicalxpress.com/tags/clinical+trials/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">clinical trials</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）证明效果不佳后，神经科学领域已经远离了</span>BACE1<span style="font-size: 18px; font-family: 宋体;">抑制剂。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">有趣的是，</span>BACE1<span style="font-size: 18px; font-family: 宋体;">也表达在一类被称为肿瘤相关巨噬细胞</span>(tumor-associated </span><a href="https://medicalxpress.com/tags/macrophages/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">macrophages</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">简称</span>TAMs)<span style="font-size: 18px; font-family: 宋体;">的免疫细胞上，这些细胞存在于肿瘤微环境（</span></span><a href="https://medicalxpress.com/tags/tumor+microenvironment/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">tumor microenvironment</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）或实体肿瘤的非癌细胞成分中。肿瘤相关的巨噬细胞（</span>TAMs<span style="font-size: 18px; font-family: 宋体;">）在胶质母细胞瘤中尤其丰富，这促使鲍士登（</span>Shideng Bao<span style="font-size: 18px; font-family: 宋体;">音译）博士领导的研究团队想知道，</span>BACE1<span style="font-size: 18px; font-family: 宋体;">抑制剂是否可以有效治疗或预防高度侵袭性的脑癌。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">主管癌症干细胞研究中心的鲍博士解释说：“</span>TAMs<span style="font-size: 18px; font-family: 宋体;">主要有两种类型，大多数</span>TAMs<span style="font-size: 18px; font-family: 宋体;">是肿瘤促进和治疗耐药性，但也有一些是肿瘤抑制。如果我们能开发出一种治疗方法来控制这种平衡从而产生更多抑制肿瘤的</span>TAMs<span style="font-size: 18px; font-family: 宋体;">也许我们就能更好地治疗胶质母细胞瘤。”。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在这项研究中，研究人员筛选了广泛的化合物，以确定最有希望的抗肿瘤促进巨噬细胞</span>(tumor-promoting macrophages<span style="font-size: 18px; font-family: 宋体;">简称</span>pTAMs) <span style="font-size: 18px; font-family: 宋体;">候选者，揭示了一种名为</span>MK-8931 (verubecestat)<span style="font-size: 18px; font-family: 宋体;">的</span>BACE1<span style="font-size: 18px; font-family: 宋体;">抑制剂。他们发现，用</span>verubecestat<span style="font-size: 18px; font-family: 宋体;">治疗人类衍生的胶质母细胞瘤</span>(</span><a href="https://medicalxpress.com/tags/glioblastoma/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">glioblastoma</span></a><span style="font-size: 18px; font-family: "times new roman";">)<span style="font-size: 18px; font-family: 宋体;">临床前模型，将</span>pTAMs<span style="font-size: 18px; font-family: 宋体;">重新编入肿瘤抑制巨噬细胞</span>(tumor-suppressing macrophages <span style="font-size: 18px; font-family: 宋体;">简称</span>sTAMs)<span style="font-size: 18px; font-family: 宋体;">。结果，更丰富的干细胞有助于摧毁肿瘤细胞，包括胶质瘤干细胞，这是一种特别具有侵略性的癌细胞，可以自我更新并重新填充肿瘤。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">鲍博士说：“我们发现这些变化显著降低了肿瘤的生长。当</span>verubecestat<span style="font-size: 18px; font-family: 宋体;">与低剂量放疗联合使用时，益处甚至更明显，因为这会增强</span>TAM<span style="font-size: 18px; font-family: 宋体;">对肿瘤（</span></span><a href="https://medicalxpress.com/tags/tumor/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">tumor</span></a><span style="font-size: 18px; font-family: "times new roman";">）的浸润。”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">还需要更多的研究，但鲍博士的研究表明</span>verubecestat<span style="font-size: 18px; font-family: 宋体;">将</span>pTAMs<span style="font-size: 18px; font-family: 宋体;">转化为</span>sTAMs<span style="font-size: 18px; font-family: 宋体;">的能力可能与三个分子的活性有关，包括</span>IL-6(<span style="font-size: 18px; font-family: 宋体;">白细胞介素</span>6)<span style="font-size: 18px; font-family: 宋体;">及其受体</span>sIL-6R<span style="font-size: 18px; font-family: 宋体;">，以及</span>STAT3(signal transducer and activator of transcription 3<span style="font-size: 18px; font-family: 宋体;">的简称，即信号转换器和转录激活因子</span>3)<span style="font-size: 18px; font-family: 宋体;">。这些分子与</span>BACE1<span style="font-size: 18px; font-family: 宋体;">一起，后者在</span>pTAMs<span style="font-size: 18px; font-family: 宋体;">上比</span>sTAMs<span style="font-size: 18px; font-family: 宋体;">表达更丰富，形成一个信号级联，最终有助于维持</span>pTAMs<span style="font-size: 18px; font-family: 宋体;">的促癌特性（</span>pro-cancer properties<span style="font-size: 18px; font-family: 宋体;">）。抑制</span>BACE1<span style="font-size: 18px; font-family: 宋体;">，就像</span>verubecestat<span style="font-size: 18px; font-family: 宋体;">一样，会阻断这种信号通路。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">鲍博士说：“</span>Verubecestat<span style="font-size: 18px; font-family: 宋体;">已经被批准用于人类，因为它之前用于阿尔茨海默病的测试。这将有助于加快我们有希望的临床前研究成果的转化。这是药物再利用的一个主要好处，它能够弥补从临床前研究到临床测试的差距，而这种差距通常是一个漫长的过程。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">鲍博士实验室的博士后研究员翟奎（</span>Kui Zhai<span style="font-size: 18px; font-family: 宋体;">）博士是这项研究的第一作者，这项研究得到了隶属于美国国家卫生研究院（</span>National Institutes of Health<span style="font-size: 18px; font-family: 宋体;">）的美国国家神经疾病与中风研究所</span>(National Institute of Neurological Disorders and Stroke)<span style="font-size: 18px; font-family: 宋体;">的部分支持。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">上述介绍，仅供参考。欲了解更多信息，敬请注意浏览</span><a href="http://dx.doi.org/10.1038/s43018-021-00267-9" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="https://medicalxpress.com/news/2021-11-drug-alzheimer-disease-glioblastoma.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">。</span> </span></p><p style="line-height: 2em;"><a href="https://medicalxpress.com/news/2021-10-cancer-cells-macrophages-growth.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">How cancer cells engineer macrophages to support cancer growth</span></a></p><p style="line-height: 2em;"><a href="http://dx.doi.org/10.1038/s43018-021-00267-9" style="font-size: 18px; font-family: "arial black", "avant garde"; text-decoration: underline;" target="_blank"><span style="font-family: "arial black", "avant garde";">Abstract</span></a><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Glioblastoma (GBM) contains abundant tumor-associated macrophages (TAMs). The majority of TAMs are tumor-promoting macrophages (pTAMs), while tumor-suppressive macrophages (sTAMs) are the minority. Thus, reprogramming pTAMs into sTAMs represents an attractive therapeutic strategy. By screening a collection of small-molecule compounds, we find that inhibiting β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) with MK-8931 potently reprograms pTAMs into sTAMs and promotes macrophage phagocytosis of glioma cells; moreover, low-dose radiation markedly enhances TAM infiltration and synergizes with MK-8931 treatment to suppress malignant growth. BACE1 is preferentially expressed by pTAMs in human GBMs and is required to maintain pTAM polarization through trans-interleukin 6 (IL-6)–soluble IL-6 receptor (sIL-6R)–signal transducer and activator of transcription 3 (STAT3) signaling. Because MK-8931 and other BACE1 inhibitors have been developed for Alzheimer’s disease and have been shown to be safe for humans in clinical trials, these inhibitors could potentially be streamlined for cancer therapy. Collectively, this study offers a promising therapeutic approach to enhance macrophage-based therapy for malignant tumors.</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-212210-1313712.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-212210-1313712.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1313666.html" target="_black">哈佛大学新的研究概述了体育锻炼与长寿的关系</a><br>下一篇：<a href="http://blog.sciencenet.cn/blog-212210-1313772.html" target="_black">二比一更好：用于绿色制氢的单原子二聚体电催化剂</a>                    <!--大赛结束-->
                                        
  
</div>
            